These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22000095)

  • 1. Initiation and reinitiation of anticoagulation therapy.
    Witt DM
    Semin Hematol; 2011 Oct; 48(4):295-301. PubMed ID: 22000095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
    Clark NP
    Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of heparins in end-stage renal disease.
    Sonawane S; Kasbekar N; Berns JS
    Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
    George-Phillips KL; Bungard TJ
    Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage.
    Koo S; Kucher N; Nguyen PL; Fanikos J; Marks PW; Goldhaber SZ
    Arch Intern Med; 2004 Jul; 164(14):1557-60. PubMed ID: 15277289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry).
    Spyropoulos AC; Turpie AG; Dunn AS; Kaatz S; Douketis J; Jacobson A; Petersen H;
    Am J Cardiol; 2008 Oct; 102(7):883-9. PubMed ID: 18805116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S; Bennett D; Smith DJ
    Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin?
    Jaff MR
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S17-21. PubMed ID: 19213061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient management of anticoagulation therapy.
    du Breuil AL; Umland EM
    Am Fam Physician; 2007 Apr; 75(7):1031-42. PubMed ID: 17427618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery.
    Douketis JD; Woods K; Foster GA; Crowther MA
    Thromb Haemost; 2005 Sep; 94(3):528-31. PubMed ID: 16268467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.
    Dumaine R; Borentain M; Bertel O; Bode C; Gallo R; White HD; Collet JP; Steinhubl SR; Montalescot G
    Arch Intern Med; 2007 Dec; 167(22):2423-30. PubMed ID: 18071163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How and when to monitor a patient treated with low molecular weight heparin.
    Boneu B; de Moerloose P
    Semin Thromb Hemost; 2001 Oct; 27(5):519-22. PubMed ID: 11668422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.